Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1099800/000109980018000029/ew10-qq32018.htm
January 2023
December 2022
November 2022
October 2022
July 2022
July 2022
May 2022
April 2022
January 2022
October 2021
![]() | Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · Fax: 949.250.2525 www.edwards.com |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1099800/000109980018000029/ew10-qq32018.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Edwards Lifesciences Corp.
Edwards Lifesciences Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More![]()
Gross Profit The increase in gross profit as a percentage of net sales for the three months ended September 30, 2018 was driven primarily by a 0.8 percentage point and 0.3 percentage point increase in United States and in international markets, respectively, due to an improved product mix, driven by THVT products.
Net Sales by Product Group (dollars in millions) Table of Contents Table of Contents Transcatheter Heart Valve Therapy Net sales of THVT products increased for the three and nine months ended September 30, 2018 due primarily to: higher sales of the Edwards SAPIEN 3 valve across all regions, particularly the United States and Japan, driven by strong therapy adoption; and foreign currency exchange rate fluctuations, which increased net sales for the nine months ended September 30, 2018 by $27.6 million, due primarily to the strengthening of the Euro against the United States dollar.
On December 22, 2017, SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118") was issued to address the application of generally accepted accounting principles in the United States of America in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Act.
The expense in the year-to-date period of 2018 was primarily due to the increase in the fair value of contingent consideration liabilities associated with the December 2017 acquisition of Harpoon Medical Inc., and the achievement by Valtech Cardio Ltd. of a regulatory milestone.
The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law.
The effective rate for the...Read more
Consolidated Cash Flows - For...Read more
Customers consumed this inventory during...Read more
Customers consumed this inventory during...Read more
In addition, the effective rate...Read more
The Credit Agreement provides up...Read more
Net cash used in financing...Read more
Table of Contents Table of...Read more
Our effective income tax rate...Read more
In addition, foreign currency exchange...Read more
The impact of foreign currency...Read more
The 2017 Act reduced the...Read more
As of September 30, 2018,...Read more
Financial Highlights Our sales growth...Read more
Net cash provided by investing...Read more
We operate in an international...Read more
We strive to resolve open...Read more
New Accounting Standards For information...Read more
In February 2018, we received...Read more
In April 2018, we received...Read more
As a result of new...Read more
Driven by a passion to...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Edwards Lifesciences Corp provided additional information to their SEC Filing as exhibits
Ticker: EW
CIK: 1099800
Form Type: 10-Q Quarterly Report
Accession Number: 0001099800-18-000029
Submitted to the SEC: Thu Oct 25 2018 12:39:02 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Sunday, September 30, 2018
Industry: Orthopedic Prosthetic And Surgical Appliances And Supplies